Log in or Sign up for Free to view tailored content for your specialty!
Schizophrenia News
An anomalous iris finding: A case of Wölfflin nodules
Wölfflin nodules are light-colored, peripheral iris nodules that are found in 10% of healthy individuals and almost exclusively in patients with light irides.
Two antipsychotic drugs prolong QTc interval, may cause arrhythmias, sudden cardiac death
The antipsychotic drugs quetiapine and haloperidol were associated with severe QT prolongation, ventricular arrhythmias and sudden cardiac death, researchers reported in HeartRhythm.
Log in or Sign up for Free to view tailored content for your specialty!
Weekly risperidone achieves similar drug levels as daily dose in phase 3 trial
An investigational, weekly oral dose of risperidone for schizophrenia achieved drug levels comparable to daily Risperdal in a phase 3 study involving Lynx, a long-acting drug delivery platform developed by Lyndra Therapeutics.
FDA grants breakthrough device designation to digital therapeutic for schizophrenia
The FDA has granted breakthrough device designation for CT-155, an investigational prescription digital therapeutic co-developed by Click Therapeutics and Boehringer Ingelheim to treat negative symptoms of schizophrenia.
Bristol Myers Squibb announces merger with Karuna Therapeutics
Bristol Myers Squibb and Karuna Therapeutics Inc. announced a definitive merger agreement that includes Karuna’s lead asset, a muscarinic receptor agonist to treat schizophrenia and Alzheimer’s disease psychosis.
FDA clears neuromelanin MRI analysis platform for evaluating neurological disorders
The FDA has cleared for marketing “the world’s first” cloud-based software for clinical analysis of neuromelanin-sensitive MRI scans, according to a press release from the manufacturer.
AbbVie acquires Cerevel, boosting roster of therapeutic candidates
AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.
FDA accepts KarXT new drug application for treating schizophrenia
The FDA has accepted a new drug application from Karuna Therapeutics for KarXT, an investigational muscarinic antipsychotic for the treatment of schizophrenia in adults, the company announced in a press release.
$10M research initiative will fund research on neuroinflammation
The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.
Brilaroxazine shows promise for schizophrenia in pivotal phase 3 trial
Brilaroxazine, a potential new treatment for schizophrenia, significantly improved symptoms and was well-tolerated in a pivotal phase 3 trial, according to a press release from its manufacturer.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read